Paul Watt - Phylogica Insider

PYC -- Australia Stock  

AUD 0.03  0.001  3.45%

  Executive
Dr. Paul Michael Watt is NonExecutive Director of Phylogica Ltd. He is a graduate from The University of Western Australia. He completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities. He discovered three novel genes, including the yeast homologue of the human Bloom and Werner syndrome genes involved in cancer susceptibility. He is an Honorary Research fellow at the Telethon Institute for Child Health Research and an Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Dr. Watt has published more than 45 peer reviewed scientific papers. Dr. Watt has more than 12 years experience in commercializing intellectual property and is the primary inventor on 20 patents. He founded InfaMed Ltd., now owned by Avita Medical Ltd.
Age: 47  Executive Since 2016      
61 8 9489 7777  http://www.phylogica.com.au

Management Efficiency

The company has return on total asset (ROA) of (85.88) % which means that it has lost $85.88 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (91.1) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Kevin CorballyAustralia and New Zealand Banki
2018
Hugo BagueRio Tinto Limited
2013
David StephenWestpac Banking Corporation
2018
Vittoria ShorttCommonwealth Bank of Australia
2015
Andrew HardingRio Tinto Limited
2013
Michael LiarakosAustralia and New Zealand Banki
2016
Andrew CuthbertsonCSL Limited
2000
Eleanor EvansRio Tinto Limited
2013
Marcin FirekWoolworths Group Limited
2017
Paul MeadowsWesfarmers Limited
2010
Debra ValentineRio Tinto Limited
2009
Clare McManusCommonwealth Bank of Australia
2017
Vera KirikovaRio Tinto Limited
2017
Kate GriffithsBHP Billiton Limited
2014
Lyn CobleyWestpac Banking Corporation
2015
Luigi MottoliniWesfarmers Limited
2016
Christine ParkerWestpac Banking Corporation
2011
Caryn KatsikogianisWoolworths Group Limited
2016
Arnaud SoiratRio Tinto Limited
2016
Julie GalliganTransurban Group
2012
Lisa TobinTransurban Group
2013

Entity Summary

Phylogica Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. It has approximately 12 patent families comprising multiple grantedallowed patents in the United States and Australia, which cover methods of making the Phylomer libraries methods of screening them and composition-of-matter claims for Phylomer libraries and individual Phylomer peptides discovered for therapeutic and diagnostic applications. Phylogica operates under Biotechnology classification in Australia and traded on Australian Securities Exchange.Phylogica Limited (PYC) is traded on Australian Securities Exchange in Australia. It is located in Telethon Kids Institute and employs 5 people.

Phylogica Limited Leadership Team

Douglas Wilson, Executive Chairman of the Board
Bernard Hockings, Director
Paul Watt, Chief Scientific Officer
Sahm Nasseri, Non-Executive Director
Kevin Hart, CFO, Company Secretary
Graeme Boden, CFO, Company Secretary
Rudi Michelson, IR Contact Officer
Alan Tribe, Chairperson of the Board
Rick Kendall, Independent Non-Executive Director
Stephanie Unwin, Non-Executive Director
Robert Hayes, Chief Scientific Officer, Director
Bruce McHarrie, Non-Executive Director
Natasha Forde, Joint Company Secretary
Richard Hopkins, CEO, Executive Director
Michael Williams, Non-Executive Director
Jeremy CurnockCook, Non-Executive Director
Rohan Hockings, Director

Stock Performance Indicators

Current Sentiment - PYC

Phylogica Limited Investor Sentiment

Most of Macroaxis users are at this time bullish on Phylogica Limited. What is your perspective on investing in Phylogica Limited? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
3 days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
3 days ago
Traded for 156.0
F   
Purchased over 300 shares of
3 days ago
Traded for 9.81
C   
Purchased over 40 shares of
3 days ago
Traded for 74.735
GM   
Purchased over 70 shares of
3 days ago
Traded for 36.08
Additionally take a look at Your Equity Center. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Search macroaxis.com